spacer
home > epc > winter 2016 > latest on life sciences
PUBLICATIONS
European Pharmaceutical Contractor

Latest on Life Sciences

The CMS Global Lifesciences Forum took place in Frankfurt, Germany on 9 November 2015, with the official report released a month later. Topics such as mergers and acquisitions (M&A), liability risks, marketing and distribution, eHealth and mHealth, big data, nutraceuticals and the protection of trade secrets were explored.

The M&A panel looked in detail at the medical devices and pharmaceuticals markets. The panel referred to M&A as “the lifeblood of the industry”, and stressed that consolidation and partnerships are vital to continued growth and success.

Successfully Managing Deals

According to Dr Max Gisbert Kley, member of the Management Board at the Freudenberg Medical Group – a family company that produces medical devices and components – the deal environment for medical devices, which has been recovering since it was hit by insecurities surrounding the Affordable Care Act in 2011, looks to be increasingly favourable.

Major opportunities can be found in the fragmented medical devices sector as it brings together scale and counter-balance consolidation on the healthcare provider side. Market leader Medtronic holds an estimated 8% market share, followed by Johnson & Johnson. While a handful of companies take a market share of 1-3% each, the remaining share of about 45% was shown to be held by thousands of smaller firms. Companies are also looking to expand their footprint and break into emerging markets.

Rise of Oncology


Dr Birgit Reitmaier, Director of Global Business Development at Merck – a leading global pharma company headquartered in Germany – has shown that the pharmaceutical market has seen an overall decline in M&A since the financial crisis.

Oncology, however, has been an area of continued strength, with deals remaining at the 8-9 per year mark. The strength of the oncology sector has encouraged companies to spend more on early-stage assets. This dynamic is leading the market towards earlier deal-making and greater risk-taking, albeit for better rewards.

Product Liability Risks


Eva Schothorst-Gransier, Partner at CMS Utrecht, and Chris Tait, European Life Science Underwriting Manager at Chubb Insurance, covered a discussion on effectively handling product liability risks. Although Europe is trying hard to harmonise legislation, they showed that courts in several jurisdictions are struggling with the interpretation of the applicable European Directives. This has been emphasised since the multi-jurisdictional cases of personal independence payment and Boston Scientific. The panel found that, at present, the risk environment is overwhelmingly advantageous for the consumer, resulting from tightening legislation as well as recent jurisprudence from the European Court of Justice.

The exposure to liability is significant; as a consequence, manufacturers must focus on compliance, spend properly during development and avoid cutting corners in order to avert large claims. Aside from agreeing on contractual indemnities (as far as possible), taking out proper insurance is recommended.

Going Digital

During the panel on marketing and distribution in life sciences, Dennis Kaben, Legal Director at Google Germany, showed the Forum the importance of online and mobile advertising to reach customers in a world that is increasingly connected, and where already half of all current devices are mobile. Sandra Hoyer, Head of Consumer Health and Pharma at German telecommunications firm Deutsche Telekom, emphasised that one of the biggest advances in life sciences this decade has been the advent of smartphone technology. Patients can now track a large number of variables through sensors in their phones; this advance in data collection has driven innovation in the eHealth and mHealth sectors.

Furthermore, devices will continue to get smaller and more inconspicuous. A milestone of this trend is a digital pill which was recently given FDA approval; it combines a regular pill with an ingestible sensor. With the addition of an adhesive patch and a mobile application, this solution is able to track ingestion of the pill as well as vitals, and then transmit data from within the body. Klaus Rupp, Head of Unit Care Management at Techniker Krankenkasse, discussed telemedicine and the benefits this could have for busy patients. Although telemedicine is far from becoming the norm, it is certainly a leap forward for eHealth.

All About the Cloud


Big data was also an important discussion point this year. The use of big data is certainly attractive to the pharma industry, the idea being that it can be accessed at will and used to diagnose health issues and discern best treatment practice based on the huge amount of historic data currently stored.

Issues of data protection and methods of storage engendered a vigourous debate between Dr Matthieu P Schapranow, Programme Manager of E-Health at the Hasso Plattner Institute, the German University specialised in IT Systems Engineering, and Michael Dörr, Director of Supplier Relations, Central Eastern Europe at IMS Health, a global information solution provider for the pharma and healthcare industries. Algorithms are being produced that can sift through data more efficiently than ever; these can provide accurate solutions to health issues based on historic cases with a high degree of reliability, according to Schapranow. Dörr, however, pointed out that with such intelligent algorithms, there are dangerous implications for data protection as they risk unintentional de-anonymisation. Dr Schapranow suggested that the issue of de-anonymisation could be addressed by patients providing authorisation for medical data to be used in such circumstances – a similar concept to a donor card.

Another contentious point on the subject of big data was the clash between cloud storage and local storage. Cloud storage seems most attractive as large amounts of data need not be stored on site. It was argued, however, that cloud storage for life sciences involves long data transfer times at hospitals or labs due to sheer volume of data, whereas data processing on site would only require the transfer of comparably small algorithms.

Legal Challenges of Nutraceuticals

Simone Pelkmans, General Counsel Foods – Baking, Cooking and Spreads and Dressings at Unilever Netherlands, and Pascal Buergin, Head of Law and Compliance at Bayer Consumer Care, discussed a fairly new branch of the life sciences tree: nutraceuticals, or the role that foods and nutritional supplements play in the industry.

There was a focus on the regulatory hurdles faced by multinational food companies producing nutraceuticals when marketing brands across multiple jurisdictions. They highlighted that the lack of global harmonisation when it comes to marketing and advertising health benefits must be addressed for the sector to flourish.

Protecting Business Secrets

The final topic of the day was protecting trade secrets. At present, there is no harmonisation within the EU for trade secrets best practice, as discussed by Dr Nikolas Gregor, a Senior Associate from CMS Hamburg. Currently, there is a draft EU legislation that would ensure trade secrets are treated as an intangible asset throughout the EU. This legislation would lead to substantial changes of the legal framework in many member states, especially when it comes to defining a trade secret. The suggested definition is ‘know-how and business information’ that meet the following requirements: it is not generally known to those in the specific field; it has commercial value because it is a secret; and reasonable steps can be taken to keep it a secret. These rules would, of course, have implications for the development of new drugs and, as addressed by Dr Thomas Hirse, Partner at CMS Düsseldorf, for clinical trial data.

Under the proposed definition, clinical trial data would be classified as a trade secret, – this would be problematic for the EMA initiative which aims to increase transparency. According to its Policy No. 0070 that came into force on 1 January 2015, EMA proactively publishes, through an IT system, clinical study reports supporting a new marketing authorisation application, or in the course of a post-authorisation procedure, allowing not only patients and patient groups, but also competitors, to review clinical trial data as well as preclinical data and other sensitive proprietary information. As such data and information are clearly regarded as trade secrets under the draft EU Directive, this causes a conflict. However, the EMA does not regard such data and information (including clinical trial data) as commercially confidential information for which the clinical study reports can be redacted.

Innovation to Come

At the end of the day’s proceeding, Willem Hoorneman, Partner and Head of the CMS Lifesciences Group, thanked the audience, speakers and panellists, saying: “We were proud to see so many industry experts attend the forum. The points discussed are at the cutting edge of our industry and will be shaping it for years to come. We look forward to seeing the innovative ideas discussed over the course of the day implemented in the coming year with great excitement.”


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Willem Hoorneman is a Partner in the Intellectual Property (IP) and Technology, Media and Communications practice group and leads the CMS Lifesciences Sector Group. With 25 years' experience in IP, and author of patent chapters in the leading handbook on software protection in the Netherlands, he is considered a pre-eminent IP lawyer.

Jens Wagner is Partner specialising in competition and IP. He advises and represents life sciences companies (pharmaceuticals, biotechnology and medical products). Jens has been with CMS since 1998.

Dr Roland Wiring is Partner specialising in unfair competition, consulting and representation in the areas of life sciences and medical devices – in particular, health advertising, pharma and medicine law, medical devices law, product liability, healthcare compliance and competition law. He has been at CMS since 2008.

spacer
Willem Hoorneman
spacer
spacer
spacer
Roland Wiring
spacer
spacer
spacer
Jens Wagner
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PPMA Group Industry Awards 2019

PPMA Group is today issuing a ‘Final Call for Entries’ to the 2019 PPMA Group Industry Awards. All companies within the packaging and processing sector are invited to submit their FREE submission by the deadline of 17 July 2019.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement